Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:8850 |
Name | salivary gland cancer |
Definition | An oral cavity cancer that is located_in the salivary gland. |
Source | DiseaseOntology.org |
Alt Ids | DOID:9148 DOID:8873 |
Path | disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer oral cavity cancer salivary gland cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
BRAF V600E | Vemurafenib | salivary gland cancer | predicted - sensitive | detail... |
HRAS mutant | Tipifarnib | salivary gland cancer | predicted - sensitive | detail... |
RET fusion | Selpercatinib | salivary gland cancer | sensitive | detail... |
BRAF V600E | Dabrafenib + Trametinib | salivary gland cancer | sensitive | detail... |
EML4 - ALK | Alectinib | salivary gland cancer | predicted - sensitive | detail... |
FGFR2 Y375C | Erdafitinib | salivary gland cancer | predicted - sensitive | detail... |
FGFR2 W72C FGFR2 E565A | Erdafitinib | salivary gland cancer | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01316757 | Phase II | Carboplatin + Cetuximab + Erlotinib + Paclitaxel | Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer | Completed | USA | 0 |
NCT01969578 | Phase II | Bicalutamide + Triptorelin Carboplatin + Paclitaxel Cisplatin + Doxorubicin | Androgen Deprivation Therapy in Advanced Salivary Gland Cancer | Completed | NLD | ITA | HUN | GRC | FRA | DEU | BEL | AUT | 0 |
NCT02091141 | Phase II | Erlotinib Alectinib Cobimetinib + Vemurafenib Pertuzumab + Trastuzumab Vismodegib Atezolizumab | My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors | Completed | USA | 0 |
NCT02538510 | Phase Ib/II | Pembrolizumab + Vorinostat | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02576431 | Phase II | Larotrectinib | A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors (NAVIGATE) | Active, not recruiting | USA | TUR | SWE | SVK | ITA | IRL | FRA | ESP | DNK | DEU | CZE | CAN | BRA | BEL | AUS | ARG | 9 |
NCT02628067 | Phase II | Pembrolizumab | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | Recruiting | USA | POL | NOR | NLD | ITA | ISR | FRA | ESP | DNK | DEU | BRA | AUS | 9 |
NCT02636036 | Phase I | Enadenotucirev + Pembrolizumab | Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors | Completed | USA | 0 |
NCT02749903 | Phase II | Enzalutamide | Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers | Unknown status | USA | 0 |
NCT02795156 | Phase II | Cabozantinib Afatinib Regorafenib | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | Completed | USA | 0 |
NCT03172624 | Phase II | Ipilimumab + Nivolumab | Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer | Active, not recruiting | USA | 0 |
NCT03319628 | Phase I | XMT-1536 | First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b | Active, not recruiting | USA | 0 |
NCT03360890 | Phase II | Docetaxel + Pembrolizumab | Synergy of Pembrolizumab Anti-PD-1 Immunotherapy With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors | Suspended | USA | 0 |
NCT03781986 | Phase Ib/II | Alrizomadlin | APG-115 in Salivary Gland Cancer Trial | Active, not recruiting | USA | 0 |
NCT03936959 | Phase I | LY3434172 | A Study of LY3434172, a PD-1 and PD-L1 Bispecific Antibody, in Advanced Cancer | Completed | USA | FRA | BEL | AUS | 1 |
NCT04105543 | Phase I | CLR 131 | CLR 131 Combined With Radiation for Head and Neck Cancer | Completed | USA | 0 |
NCT04209660 | Phase II | Lenvatinib + Pembrolizumab | Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers | Active, not recruiting | USA | 0 |
NCT04682431 | Phase I | Pembrolizumab + PY159 PY159 | A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Terminated | USA | 0 |
NCT04704661 | Phase I | Ceralasertib + Trastuzumab deruxtecan | Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | Recruiting | USA | 0 |
NCT04895735 | Phase II | Pembrolizumab + Pemetrexed Disodium | Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer | Recruiting | USA | 0 |
NCT05408845 | Phase II | Docetaxel + Trastuzumab Ado-trastuzumab emtansine | Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer | Recruiting | USA | 0 |
NCT05608876 | Phase II | Tigilanol tiglate | A Clinical Study to Investigate the Efficacy of Tigilanol Tiglate Directly in Head and Neck Cancer | Recruiting | GBR | AUS | 0 |
NCT05669664 | Phase II | Darolutamide + Leuprolide | Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers | Recruiting | USA | 0 |
NCT05884320 | Phase II | Sacituzumab govitecan-hziy | Phase II Trial of Sacituzumab Govitecan in Recurrent and/or Metastatic Salivary Gland Cancers | Recruiting | USA | 0 |
NCT06638931 | Phase II | Nivolumab | Agnostic Therapy in Rare Solid Tumors (ANTARES) | Recruiting | BRA | 0 |